Prosecution Insights
Last updated: August 16, 2026
Application No. 17/633,067

METHODS OF IMPROVING ORGAN FUNCTION

Final Rejection §103
Filed
Feb 04, 2022
Priority
Aug 08, 2019 — provisional 62/884,583 +1 more
Examiner
AUDET, MAURY A
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cedars-Sinai Medical Center
OA Round
2 (Final)
50%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
74%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
476 granted / 952 resolved
-10.0% vs TC avg
Strong +24% interview lift
Without
With
+23.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
38 currently pending
Career history
1002
Total Applications
across all art units

Statute-Specific Performance

§101
4.2%
-35.8% vs TC avg
§103
32.9%
-7.1% vs TC avg
§102
12.2%
-27.8% vs TC avg
§112
33.9%
-6.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 952 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-3,11-16,32-34 and 36-37 are pending and examined on the merits. Applicant is required to remove any/all Trademarks form the claims/description. Election/Restrictions-Withdrawn Upon further consider the choice of C1 esterase inhibitor is open, including variants within a pool thereof (see e.g. relevant background sections within U.S. Patent Publication No: 20220265786). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-3,11-16,32-34 and 36-37 is/are rejected under 35 U.S.C. 103 as being unpatentable over the same prior art: PNG media_image1.png 42 511 media_image1.png Greyscale applied by the U.S. International Authority over the same/nearly same subject matter scope claimed here. Such is of record and has been incorporated herein by reference in it’s entirety. The claimed invention is hereby found prima facie obvious over the prior art recited therein, as lacking inventive step under International Law. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MAURY AUDET whose telephone number is (571)272-0960. The examiner can normally be reached on M-Th. 7AM-5:30PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko Garyu can be reached on 571-270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /MAURY A AUDET/Primary Examiner, Art Unit 1654
Read full office action

Prosecution Timeline

Feb 04, 2022
Application Filed
Mar 20, 2025
Examiner Interview (Telephonic)
Apr 11, 2025
Examiner Interview Summary
Jul 08, 2025
Non-Final Rejection mailed — §103
Oct 08, 2025
Response Filed
Aug 07, 2026
Examiner Interview (Telephonic)
Aug 13, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12606594
HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES
4y 2m to grant Granted Apr 21, 2026
Patent 12606592
TRIPLE G-C-T BASE CODED NUCLEOBASE AMINO ACID, ITS SYNTHESIS AND PEPTIDE FORMATION
3y 6m to grant Granted Apr 21, 2026
Patent 12570695
BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2
4y 1m to grant Granted Mar 10, 2026
Patent 12569532
BRAIN FUNCTION REGULATING AGENT, AND FOOD OR BEVERAGE PRODUCT CONTAINING SAME
3y 5m to grant Granted Mar 10, 2026
Patent 12551532
LONG-ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF
1y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
50%
Grant Probability
74%
With Interview (+23.8%)
3y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 952 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month